180 related articles for article (PubMed ID: 32702387)
1. Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's disease.
Rolfes S; Munro DAD; Lyras EM; Matute E; Ouk K; Harms C; Böttcher C; Priller J
Neurobiol Dis; 2020 Oct; 144():105024. PubMed ID: 32702387
[TBL] [Abstract][Full Text] [Related]
2. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
3. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
Popovic N; Maingay M; Kirik D; Brundin P
Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
[TBL] [Abstract][Full Text] [Related]
5. Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease.
Kohl Z; Kandasamy M; Winner B; Aigner R; Gross C; Couillard-Despres S; Bogdahn U; Aigner L; Winkler J
Brain Res; 2007 Jun; 1155():24-33. PubMed ID: 17512917
[TBL] [Abstract][Full Text] [Related]
6. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
7. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.
Murphy KP; Carter RJ; Lione LA; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ
J Neurosci; 2000 Jul; 20(13):5115-23. PubMed ID: 10864968
[TBL] [Abstract][Full Text] [Related]
8. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
Rattray I; Smith EJ; Crum WR; Walker TA; Gale R; Bates GP; Modo M
PLoS One; 2013; 8(12):e84726. PubMed ID: 24367693
[TBL] [Abstract][Full Text] [Related]
9. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
Ransome MI; Hannan AJ
Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
[TBL] [Abstract][Full Text] [Related]
10. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
11. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
[TBL] [Abstract][Full Text] [Related]
12. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.
Gil JM; Leist M; Popovic N; Brundin P; Petersén A
BMC Neurosci; 2004 May; 5():17. PubMed ID: 15134587
[TBL] [Abstract][Full Text] [Related]
13. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.
Cabezas-Llobet N; Vidal-Sancho L; Masana M; Fournier A; Alberch J; Vaudry D; Xifró X
Mol Neurobiol; 2018 Nov; 55(11):8263-8277. PubMed ID: 29526016
[TBL] [Abstract][Full Text] [Related]
14. Direct Visualisation of Abnormal Dendritic Spine Morphology in the Hippocampus of the R6/2 Transgenic Mouse Model of Huntington's Disease.
Bulley SJ; Drew CJ; Morton AJ
J Huntingtons Dis; 2012; 1(2):267-73. PubMed ID: 25063335
[TBL] [Abstract][Full Text] [Related]
15. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model.
Harrison DJ; Busse M; Openshaw R; Rosser AE; Dunnett SB; Brooks SP
Exp Neurol; 2013 Oct; 248():457-69. PubMed ID: 23911978
[TBL] [Abstract][Full Text] [Related]
16. Alterations in Hippocampal Inhibitory Synaptic Transmission in the R6/2 Mouse Model of Huntington's Disease.
Dargaei Z; Liang X; Serranilla M; Santos J; Woodin MA
Neuroscience; 2019 Apr; 404():130-140. PubMed ID: 30797895
[TBL] [Abstract][Full Text] [Related]
17. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
Hannan AJ; Ransome MI
J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
[TBL] [Abstract][Full Text] [Related]
18. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity.
Anglada-Huguet M; Vidal-Sancho L; Giralt A; García-Díaz Barriga G; Xifró X; Alberch J
Neurobiol Dis; 2016 Nov; 95():22-34. PubMed ID: 26369879
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
